iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update Bryan, TX /

iBio Reports Fiscal Third Quarter 2021 Financial

Results and Provides Corporate Update

Bryan, TX / May 17, 2021 / (GLOBE NEWSWIRE) /

iBio, Inc. (NYSEA:IBIO) ("iBio" or the

"Company"), a biotech innovator and biologics contract manufacturing organization, today announced its financial results

for the fiscal quarter ended March 31, 2021.

"Our focus on strategy execution was reflected

in our third quarter results as we advanced our second-generation COVID-19 vaccine candidate, defended our intellectual property rights,

and achieved strong year-over-year revenue growth while adding new development services clients," said Tom Isett, Chairman &

CEO of iBio. "Also, more recently, we saw continued progress on new product and pipeline additions, including line extensions to

our Bioanalytical Services offering, and a planned investment in the establishment of a new Drug Discovery team. Importantly, we believe

that when our new discovery capabilities are installed, we will be able to more fully leverage the many speed-to-clinic'

advantages conveyed by our proprietary FastPharming System."

Fiscal Third Quarter and Recent Business Developments:

Contract Development and Manufacturing ("CDMO")

Research & Bioprocess Products

"We are excited about the advancement of

a differentiated second-generation COVID-19 vaccine candidate," said Mr. Isett. "Additionally, we are pleased with the protection

of - and compensation for - our IP in plant-based biologics, as we further develop our FastPharming Technologies. Moreover,

we continue to see increased demand from new and existing customers for our CDMO Services, even while we are in the midst of our transformation."

With reference to the Company's planned

establishment of in-house drug discovery capabilities, Mr. Isett commented, "We believe that our investment in fast, translatable

drug discovery activities will enable us to optimally leverage our FastPharming System to create a robust pipeline of truly

innovative molecules and fast-followers, particularly in the field of oncology."

Fiscal Third Quarter and Recent Corporate Developments:

"The key additions of Martin and Rob - along

with the recruitment of many talented new employees to our R&D and Operations functions - reflect the ongoing rapid and successful

transformation of iBio," said Mr. Isett. "By further expanding the capabilities of our team this quarter, we delivered

new pipeline candidates, new service products and continued to advance other key initiatives. Clearly, our ability to execute and deliver

value to shareholders has been further elevated this quarter, and we expect that the investment in the new Drug Discovery Team will yield

significant returns as we seek to make the FastPharming System the bioprocess platform-of-choice."

For the fiscal quarter ended March 31, 2021, iBio

reported revenues of approximately $0.8 million, an increase of $0.7 million from $0.1 million in the fiscal quarter ended March 31, 2020.

To further clarify the results of its operations

for investors, from this quarter forward, iBio will include Cost of Goods Sold ("COGS") and Gross Profit line items in its

financial statements. For the three-months ended March 31, 2021, iBio reported COGS of approximately $0.5 million and gross profit of

$0.3 million, compared to COGS of $0.1 million and gross profit that was not significant for the three months ended March 31, 2020. Since

iBio's revenue is currently derived from a small number of contracts, and revenue recognition from development and manufacturing

services is generally subject to volatility due to timing, the Company expects that gross profit and gross profit percentage may fluctuate

significantly from quarter to quarter.

R&D expenses for the fiscal quarter ended

March 31, 2021 were approximately $2.2 million, compared with approximately $1.1 million in the same period of 2020. The increase in R&D

expense of approximately $1.1 million was primarily related to increases in personnel and other expenses to support the Company's

development of a portfolio of proprietary therapeutics and vaccines.

G&A expenses for the fiscal quarter ended

March 31, 2021 were approximately $5.3 million, compared with approximately $3.0 million in the same period of 2020. The increase of approximately

$2.3 million resulted primarily from increased headcount and increased operations to support the growth of the business.

Net loss attributable to iBio stockholders for

the fiscal quarter ended March 31, 2021 was approximately $7.7 million, or $0.04 per share. This compared with a net loss of approximately

$4.7 million, or $0.06 per share, in the same period of 2020.

iBio had $103.9 million in cash, cash equivalents

and debt investments as of March 31, 2021. The Company further strengthened its financial position through the aforementioned settlement

of litigation with Fraunhofer USA. The Company believes it will have sufficient resources to fund its planned operations at least through

March 31, 2023, inclusive of its planned investment in the FastPharming Discovery Platform and potential in-licensing activities.

Webcast and Conference Call

iBio management will host a webcast and conference

call at 8:00 a.m. Eastern Time today, May 17, 2021, to discuss these results and provide a corporate update.

The live and archived webcast may be accessed

on the Company's website at www.ibioinc.com under "News and Events"

in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (international) and referencing

conference code: 3085726.

iBio is a global leader in plant-based biologics

manufacturing. Its FastPharming System combines vertical farming, automated hydroponics, and novel glycosylation

technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary

products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases,

amongst others. The Company's subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing

Services, including Glycaneering Development Services for advanced recombinant protein design. For more information,

visit www.ibioinc.com.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release constitute

"forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might,"

"will," "should," "believe," "expect," "anticipate," "estimate," "continue,"

"predict," "forecast," "project," "plan," "intend" or similar expressions, or statements

regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current

estimates and assumptions and include statements regarding the planned investment in the establishment of a new Drug Discovery team, being

able to more fully leverage the many speed-to-clinic' advantages conveyed by its proprietary FastPharming

System, the planned establishment of drug discovery capabilities in San Diego, initiation of IND-enabling studies of IBIO-100 in FY 2022,

the investment in fast, translatable drug discovery activities enabling the Company to optimally leverage its FastPharming

System to create a robust pipeline of truly innovative molecules and fast-followers, particularly in the field of oncology, and the investment

in the new Drug Discovery Team yielding significant returns as the Company seeks to make the FastPharming System the bioprocess

platform-of-choice. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on

any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking

statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ

materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors

that could cause actual results to differ materially from current expectations include, among others, the ability to establish of a new

Drug Discovery team, the ability to successfully leverage the many speed-to-clinic' advantages conveyed by its proprietary

FastPharming System, the ability to establish drug discovery capabilities in San Diego, the ability to initiate IND-enabling

studies of IBIO-100 in FY 2022, the Company's ability to apply its investment in fast, translatable drug discovery activities to

optimally leverage its FastPharming System to create a robust pipeline of truly innovative molecules and fast-followers,

the Company's ability to make the FastPharming System the bioprocess platform-of-choice, the Company's ability

to obtain regulatory approvals for commercialization of its product candidates, including its COVID-19 vaccines, or to comply with ongoing

regulatory requirements, regulatory limitations relating to its ability to promote or commercialize the Company's product candidates

for specific indications, acceptance of the Company's product candidates in the marketplace and the successful development, marketing

or sale of the Company's products, the Company's ability to maintain its license agreements, the continued maintenance and

growth of its intellectual property portfolio, the Company's ability to establish and maintain collaborations, the Company's

ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, the Company's

ability to retain its key employees or maintain its NYSE American listing, and the other risk factors discussed in the Company's

most recent Annual Report on Form 10-K and the Company's subsequent filings with the SEC, including subsequent periodic reports

on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation

to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except